Unlearn Appoints Krates Ng as Chief Technology Officer to Lead Next Phase of Technological and Operational Expansion
Unlearn®, a pioneer in developing artificial intelligence solutions to optimize clinical trials, has announced the appointment of Krates Ng as its Chief Technology Officer (CTO). This strategic leadership addition comes as Unlearn continues to experience accelerated growth and market momentum, driven by increasing adoption of its AI-driven solutions designed to transform drug development.
The appointment of Ng marks a significant milestone for Unlearn as the company enters a new phase of maturity. After nearly a decade of foundational work and innovation, Unlearn is scaling its operations and expanding its technology infrastructure to support the growing demand for its solutions from pharmaceutical sponsors and clinical research organizations. As CTO, Ng will lead Unlearn’s engineering, product development, and infrastructure teams, while also collaborating cross-functionally to ensure seamless integration between the company’s R&D, commercial, and customer success initiatives.
A Strategic Inflection Point for AI in Clinical Trials
Founded with the mission to modernize and accelerate clinical trials using artificial intelligence, Unlearn has built a reputation for creating innovative technologies that can reduce trial timelines, lower costs, and increase statistical power. The company’s flagship product offering, Digital Twins, leverages proprietary machine learning models to generate patient-specific predictions, allowing for more precise and efficient clinical study designs.
According to Unlearn CEO Steve Herne, the company’s evolution from early-stage innovation to large-scale implementation demanded the addition of a seasoned technology executive with proven expertise in scaling platforms and teams.
After almost a decade, Unlearn is at an inflection point where we are advancing our mission through expanded offerings built to meet market and customer demand,” Herne stated. “With his deep experience building and scaling products and teams across markets, we’re thrilled to bring Krates on board in this next phase of our growth trajectory.”
A Track Record of Innovation and Operational Excellence
Ng brings to Unlearn more than 20 years of experience leading engineering and technology teams in high-growth environments across healthcare, enterprise software, and AI-enabled platforms. He most recently served as Chief Technology Officer at ProducePay, where he played a pivotal role in building scalable systems and integrating advanced technologies to optimize supply chain operations in agriculture.
Prior to ProducePay, Ng was Senior Vice President of Engineering at RapidAI, a leading provider of AI-based clinical decision support tools used in emergency care settings. At RapidAI, Ng led the transformation of the company’s engineering and product operations, overseeing teams responsible for developing FDA-cleared software solutions used globally in stroke and neurovascular care. Under his leadership, RapidAI significantly expanded its clinical and geographic footprint, earning recognition for its ability to drive life-saving decisions in acute care environments.
Earlier in his career, Ng co-founded CliniCast, a healthcare startup focused on applying machine learning to improve value-based oncology care. The company developed predictive analytics and clinical pathway solutions that enabled healthcare providers to deliver better outcomes at lower costs. CliniCast was acquired by a major healthcare technology firm, and its solutions were integrated into broader population health platforms.
Ng holds a Bachelor of Mathematics in Computer Science from the University of Waterloo, a globally recognized institution for technology and applied mathematics.
Vision Aligned with Mission
As Unlearn expands its commercial reach and seeks to scale its technology to support a broader range of therapeutic areas and clinical trial designs, Ng’s experience aligning product development with regulatory requirements, customer needs, and enterprise scalability will be instrumental.
In his new role as CTO, Ng will lead Unlearn’s efforts to advance the company’s AI infrastructure, optimize data pipelines, and ensure robust engineering practices are in place to support rapid product development. He will also work closely with Unlearn’s scientific leadership to translate cutting-edge research into real-world applications that meet the rigorous demands of clinical trial stakeholders—including sponsors, regulators, investigators, and patients.
Unlearn is applying cutting-edge science to one of the biggest challenges in medicine—making clinical trials faster, more efficient, and more effective,” said Ng. “Drawn to the bold vision and the strength of the team, I’m excited to join Unlearn and be a part of its story bringing powerful AI innovations into real-world clinical research.”
Scaling Innovation in a Heavily Regulated Space
Unlearn’s growth trajectory coincides with a broader industry push toward more agile and adaptive clinical trial methodologies. As pharmaceutical sponsors and biotech companies seek to reduce the time and cost associated with bringing new therapies to market, AI-powered tools such as Digital Twins are gaining traction. These synthetic control arms can reduce the number of patients needed in a traditional control group by augmenting the trial data with model-generated patient trajectories—thereby increasing efficiency without compromising scientific integrity.
However, scaling these innovations in the context of regulatory frameworks such as those governed by the FDA and EMA presents unique challenges. Ensuring that AI models are validated, transparent, and interpretable is critical to gaining regulatory acceptance. Ng’s background leading engineering teams through the development of FDA-cleared medical software makes him well-suited to navigate this complex intersection of technology and compliance.
Positioning for the Future of Drug Development
Unlearn’s decision to bring in a technology leader of Ng’s caliber reflects its commitment to building a durable, world-class infrastructure that can support both its short-term ambitions and long-term vision. The company is actively investing in talent, partnerships, and platform capabilities to support its mission of fundamentally reshaping how clinical trials are conducted.
With its recent partnerships with top pharmaceutical companies and its growing pipeline of therapeutic area applications, Unlearn is poised to become a key enabler of innovation in the life sciences ecosystem. Ng’s leadership will be essential in driving the company’s technology roadmap forward, ensuring scalability, security, and performance as Unlearn transitions from early adopters to broader market adoption.
Krates Ng’s appointment as Chief Technology Officer comes at a time when Unlearn is making strategic investments to solidify its leadership in the clinical trial technology space. With a strong foundation of scientific innovation and growing industry demand for AI-powered trial acceleration tools, Unlearn is positioning itself as a transformative force in drug development.
Ng’s track record of building high-performing teams, leading AI-driven product innovation, and delivering regulatory-grade software solutions makes him uniquely qualified to lead Unlearn’s technical and operational transformation. As he joins the executive team, Unlearn is well-equipped to continue pushing the boundaries of what is possible in clinical research—helping bring therapies to patients faster, more reliably, and with greater precision than ever before.
